#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16298	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2336	851.0	0	.	n	.	0	A69G	SNP	69	69	A	482	482	G	1028	G,A,T	748,277,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16298	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2336	851.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1863	1863	T	1040	T,C,G,A	1036,2,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16298	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2336	851.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1597	1597	C	1030	C,T	1029,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16298	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2336	851.0	0	HET	.	.	.	T454TG	.	454	454	T	867	867	T	1076	TG,T	788,264	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27678	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4044	854.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1909	1909	A	1124	A,C	1123,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27678	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4044	854.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2543	2543	C	1000	C,A	999,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27678	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4044	854.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2617	2617	A	963	A,T	961,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27678	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4044	854.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3169	3169	C	1017	C,T,A	1014,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2460	folP	852	852	99.88	folP.l6.c30.ctg.1	2275	135.0	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1249	1251	AAA	230;232;231	A;A,C;A	230;231,1;231	.	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2460	folP	852	852	99.88	folP.l6.c30.ctg.1	2275	135.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1480	1482	AGC	240;243;246	A;G;C	239;243;246	folP.WHO_N_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5746	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3924	182.8	1	SNP	p	S91F	0	.	.	271	273	TCC	822	824	TCC	205;206;206	T;C;C	205;206;206	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5746	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3924	182.8	1	SNP	p	D95G	0	.	.	283	285	GAC	834	836	GAC	207;208;209	G;A;C	207;208;209	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5746	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3924	182.8	1	SNP	p	D95N	0	.	.	283	285	GAC	834	836	GAC	207;208;209	G;A;C	207;208;209	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	2338	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1888	154.7	1	SNP	p	G45D	0	.	.	133	135	GGC	742	744	GGC	272;271;267	G;G;C	272;271;267	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1220	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1556	97.9	0	.	n	.	0	A197.	DEL	197	197	A	882	882	A	231	A	231	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5384	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3343	200.8	1	SNP	p	D86N	0	.	.	256	258	GAC	804	806	GAC	221;220;219	G;A,T,G;C	221;218,1,1;219	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5384	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3343	200.8	1	SNP	p	S87R	0	.	.	259	261	AGT	807	809	AGT	220;220;219	A;G;T	220;220;219	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5384	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3343	200.8	1	SNP	p	S87W	0	.	.	259	261	AGT	807	809	AGT	220;220;219	A;G;T	220;220;219	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5384	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3343	200.8	1	SNP	p	S87I	0	.	.	259	261	AGT	807	809	AGT	220;220;219	A;G;T	220;220;219	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5384	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3343	200.8	1	SNP	p	S88P	0	.	.	262	264	TCC	810	812	TCC	219;222;222	T;C,G;C	219;221,1;222	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4684	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3121	187.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1772	1774	GGC	277;276;275	G,C;G;C,G	276,1;276;274,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4388	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	191.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1524	1526	GCA	246;245;250	G;C,T,A;A	246;243,1,1;250	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4388	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	191.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1527	1529	ATC	249;250;248	A;T,G;C,A	249;249,1;247,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4388	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	191.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1539	1541	GTG	242;245;241	G;T;G	242;245;241	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4388	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	191.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1539	1541	GTG	242;245;241	G;T;G	242;245;241	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4388	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	191.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2043	2045	ACC	263;262;263	A,G;C;C	261,2;262;263	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4388	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	191.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2097	2099	GCG	243;240;240	G,T;C;G	242,1;240;240	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4388	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	191.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2097	2099	GCG	243;240;240	G,T;C;G	242,1;240;240	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4388	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	191.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2220	2222	GGC	239;240;239	G;G,A;C	239;239,1;239	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4388	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	191.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2229	2231	GGC	247;247;248	G,T;G;C,A,T	246,1;247;246,1,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4388	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	191.4	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2247	2249	CTG	242;242;242	C;T,C;G	242;241,1;242	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6232	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3763	206.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	2040	2042	CCG	251;255;255	C,T;C;G	250,1;255;255	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2738	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2403	142.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	921	921	C	203	C	203	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	A251V	NONSYN	751	753	GCG	6	8	GTG	1;1;1	G;T;G	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	V258L	NONSYN	772	774	GTA	27	29	TTA	22;25;26	T,G;T;A	21,1;25;26	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	72	74	CAT	64;64;64	C,G;A;T	63,1;64;64	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	D274S	NONSYN	820	822	GAT	75	77	AGT	64;64;64	A;G;T	64;64;64	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	84	86	TAC	65;65;65	T,C;A;C	64,1;65;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	R307A	NONSYN	919	921	AGA	174	176	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	T311A	NONSYN	931	933	ACA	186	188	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	E312D	NONSYN	934	936	GAA	189	191	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	F314I	NONSYN	940	942	TTC	195	197	ATC	3;3;3	A;T;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	A316S	NONSYN	946	948	GCG	201	203	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	V318A	NONSYN	952	954	GTC	207	209	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	G319S	NONSYN	955	957	GGC	210	212	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	G320A	NONSYN	958	960	GGT	213	215	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	280	porB1a	984	239	90.79	porB1a.l6.c17.ctg.2	295	28.9	0	.	p	.	0	G322V	NONSYN	964	966	GGT	219	221	GTT	2;2;3	G;T;T	2;2;3	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3222	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1978	202.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	571	573	GAA	312;309;306	G;A;A	312;309;306	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3222	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1978	202.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	859	861	GAT	277;279;279	G,A;A;T	276,1;279;279	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3222	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1978	202.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	982	984	TCA	282;280;283	T,G;C;A	281,1;280;283	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3222	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1978	202.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1111	1113	GTC	271;271;268	G;T,A;C	270;270,1;268	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3222	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1978	202.3	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1123	1125	TCT	258;261;264	T;C;T	258;261;264	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3222	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1978	202.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1441	1443	GCA	257;253;257	G;C;A	257;253;257	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3222	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1978	202.3	1	SNP	p	G120K	1	.	.	358	360	AAG	817	819	AAG	270;274;273	A;A;G	270;274;273	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3222	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1978	202.3	1	SNP	p	A121D	1	.	.	361	363	GAC	820	822	GAC	272;274;273	G;A;C,T	271;274;272,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3222	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1978	202.3	1	SNP	p	D121N	0	.	.	361	363	GAC	820	822	GAC	272;274;273	G;A;C,T	271;274;272,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10546	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5384	244.6	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2290	2292	AAT	298;296;296	A;A;TAAA,TAA	298;296;279,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1530	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1576	121.1	1	SNP	p	V57M	1	.	.	169	171	ATG	729	731	ATG	264;264;266	A;T,G;G	264;263,1;266	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
